Tirzepatide is a dual-agonist peptide that targets both GLP-1 and GIP receptors with engineered affinity ratios
[DOI] [PubMed] [Google Scholar] 24.Xiang X., Lang M., Li Y., Zhao X., Sun H., Jiang W., Ni L., Song Y
Another factor is the method of administration
This is not a fair comparison
Clinical studies show that diabetic patients using dulaglutide lose around eight to 11 pounds of their body weight, while those without type 2 diabetes using semaglutide can achieve weight loss of 15 percent or more, especially at higher doses approved for weight management. The greater efficacy of semaglutide (Ozempic) makes it the preferred choice for patients focused on significant weight loss
Next, receive a customized treatment plan based on lab work, body composition, and lifestyle habits